Cytoreductive Surgery (CRS)
A debulking surgery primarily used for peritoneal mesothelioma, removing visible tumors from the abdominal cavity, often combined with HIPEC.
SurgeryOverview
Cytoreductive surgery (CRS) involves removing all visible tumors from the abdominal cavity. It is the primary surgical treatment for peritoneal mesothelioma and is almost always combined with heated intraperitoneal chemotherapy (HIPEC) to kill any remaining microscopic cancer cells.
Who May Be a Candidate
- Peritoneal mesothelioma patients
- Limited disease spread (PCI score typically <20)
- Good overall health (ECOG 0-1)
- No distant metastases
- Epithelioid cell type preferred
How It Works
The surgeon systematically examines the entire abdominal cavity and removes all visible tumor deposits. This may include removal of affected organs or organ linings (peritonectomy). After maximum tumor removal, heated chemotherapy is circulated throughout the abdomen.
Procedure Steps
- Midline abdominal incision
- Complete exploration of abdominal cavity
- Assessment of disease extent (PCI score)
- Removal of all visible tumor (peritonectomy procedures)
- Removal of affected organs if necessary
- HIPEC administration for 60-90 minutes
- Abdominal closure
Benefits
- Can achieve complete visible tumor removal
- Combined with HIPEC provides excellent local control
- Significantly improves survival for peritoneal mesothelioma
- Some patients achieve long-term remission
Risks & Side Effects
- Major surgery with significant morbidity
- Bleeding
- Infection
- Anastomotic leaks
- Prolonged recovery
- Kidney or liver effects from HIPEC
Recovery
Hospital stay is typically 10-14 days. Full recovery takes 2-3 months. Patients often need nutritional support initially. Return to normal activities is gradual.
Expected Outcomes
Combined CRS/HIPEC achieves median survival of 53-92 months in optimal candidates. Some centers report 5-year survival rates of 50% or higher. Complete cytoreduction is the most important predictor of long-term survival.
Finding Treatment
This procedure is typically performed at specialized mesothelioma treatment centers with experienced surgical teams. Consulting with a mesothelioma specialist is the first step in determining if this treatment is appropriate for your situation.
Treatment Q&A
Frequently Asked Questions
What is the life expectancy after cytoreductive surgery?
Cytoreductive surgery with HIPEC for peritoneal mesothelioma shows median overall survival of 53 months in people with the disease. Studies report 5-year overall survival rates exceeding 69% for peritoneal mesothelioma and up to 80% with added chemotherapy. For peritoneal metastases from other cancers like colorectal, median survival ranges from 22 to 52 months, with 5-year rates of 27-60% depending on tumor burden and resection completeness. Outcomes vary by cancer type, disease extent, and treatment details.
How risky is HIPEC surgery?
Evidence from large series shows that combined cytoreductive surgery and HIPEC is a major operation with reported overall complication (morbidity) rates around 30% to 70% and treatment‑related death (mortality) in roughly 0% to 18%, depending on cancer type, disease extent, and center experience. Common issues include abdominal pain, fatigue, digestive changes, low blood counts, infections, bleeding, and slower return of bowel function, while more serious but less common problems include blood clots, anastomotic leaks, organ injury, and pneumonia. HIPEC also carries specific risks from heated chemotherapy such as temporary kidney strain, fluid and electrolyte imbalance, and hematologic toxicity, which some studies describe in 4% to 39% of people. Long‑term risks can include scar tissue (adhesions) that cause chronic abdominal pain or bowel problems, and there remains a risk of cancer recurrence despite treatment. Outcomes and safety reported in the literature are generally better in high‑volume centers using strict protocols and in people with limited disease and good overall health.
What is cytoreductive surgery for mesothelioma?
Cytoreductive surgery for mesothelioma is an extensive operation that removes as much visible cancer as possible from the abdominal cavity in people with peritoneal mesothelioma. Surgeons often remove affected parts of the peritoneum (the abdominal lining) and sometimes sections of organs such as the bowel, spleen, or colon if cancer has spread there. This procedure is frequently combined with hyperthermic intraperitoneal chemotherapy (HIPEC), in which heated chemotherapy is circulated in the abdomen to attack remaining microscopic cancer cells. Studies report that this combined approach can lead to median overall survival of roughly 35 to 50 months or more, especially when surgeons achieve near-complete removal of visible disease.
How long does it take to recover from cytoreductive surgery?
Recovery from cytoreductive surgery is typically measured in months rather than weeks. Hospital stays often range from about 5 to 21 days, depending on the center and the extent of surgery, with people gradually regaining strength once they return home. Multiple studies and cancer centers report that most people recover to near preoperative levels of functioning within about 3 to 6 months, although fatigue and reduced activity are common during the first 2 to 3 months. In a large quality of life study that included people with mesothelioma, survivors had returned to about 56% of normal activity at 3 months, 70% at 6 months, and roughly 73% by 1 year. Full internal healing and a stable routine, including work and social activities, may continue to improve over 6 to 12 months.